Company insiders at Onconova Therapeutics, Inc. (NASDAQ:ONTX) have increased their position in the stock by 48.14% over the past 6 months. Insiders now own 5.30% of total outstanding shares, according to the latest filings with the SEC.
University of Michigan professor and noted insider trading researcher discovered that when insiders bought shares of their own companies, the stocks outperformed the total market by 8.9% over the next 12-month period. When they sold shares, the stock underperformed 5.4%.
Onconova Therapeutics, Inc. (NASDAQ:ONTX) stands -5.00% away from its 50-day simple moving average and also -20.89% away from the 200-day average. Recently, the equity stands -68.07% away from the 52-week high and 15.17% from the 52-week low. The RSI (Relative Strength Index), an indicator that shows price strength by comparing upward and downward close-to-close movements is 51.05.
Wall Street analysts on the sell-side covering shares of Onconova Therapeutics, Inc. (NASDAQ:ONTX) have a mean recommendation of 2.00 on the shares. This is based on a numerical chart where each stock recommendation (Buy,Sell,Hold) is translated into a numerical equivalent. A low number indicates a Buy and a higher number a Sell. In terms of where analysts see the stock headed, they have a consensus price target of $8.00 on the shares.